What is the recommended management for an acute rheumatoid arthritis flare, including NSAIDs, oral glucocorticoids, intra‑articular steroids, and adjustments to disease‑modifying antirheumatic drugs?

Management of Acute Rheumatoid Arthritis Flare

For an acute RA flare, immediately administer oral glucocorticoids at ≤0.5 mg/kg/day prednisone equivalent for 1–2 weeks while simultaneously reassessing and escalating your DMARD regimen if disease activity has not been adequately controlled. 1

Immediate Flare Management

Glucocorticoid Administration

• Prescribe oral glucocorticoids at a dose not exceeding 0.5 mg/kg/day (typically 20–40 mg prednisone daily for most adults) for a short course of 1–2 weeks to rapidly suppress the polyarticular flare 1.
• This approach provides rapid symptom relief while you address the underlying inadequate disease control 1.
• Intra-articular glucocorticoid injections should be used for oligoarticular flares (when only a few joints are involved) as part of your treatment strategy, as they increase suppression of arthritis and retard joint destruction 2.

NSAIDs Role

• NSAIDs may be used for symptomatic relief during flares, but they do not modify disease progression 3.
• The goal is to achieve disease control through aggressive DMARD therapy, which eliminates the need for ongoing NSAIDs 4.

Reassess and Escalate DMARD Therapy

Critical Timing

• A flare signals that your current DMARD regimen is inadequate 5.
• If no improvement occurred by 3 months of current therapy, or if the treatment target (remission or low disease activity) was not reached by 6 months, you must adjust therapy immediately 5.

Escalation Algorithm Based on Current Treatment

If patient is on csDMARD monotherapy (e.g., methotrexate alone):

• Without poor prognostic factors: Add or switch to another csDMARD (leflunomide, sulfasalazine, or triple therapy) 5.
• With poor prognostic factors (high-titer RF/anti-CCP, high disease activity, early erosions, or failure of two csDMARDs): Add a bDMARD or tsDMARD to the csDMARD backbone immediately 5.

If patient is already on a bDMARD or tsDMARD:

• Switch to another bDMARD (different or same class) or to a tsDMARD 5.
• After failure of a single TNF inhibitor, you may either switch to a different mechanism of action (IL-6 inhibitor, abatacept, JAK inhibitor) or try a second TNF inhibitor 5.

Specific DMARD Options

• bDMARD choices: TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, IL-6 receptor inhibitors (tocilizumab, sarilumab), or rituximab 5, 6.
• tsDMARD choices: JAK inhibitors (tofacitinib, baricitinib, filgotinib, upadacitinib), though you must carefully consider risks of major cardiovascular events, malignancies, and thromboembolic events, particularly in older patients with cardiovascular risk factors 6.
• All bDMARDs and tsDMARDs should be combined with a csDMARD (preferably methotrexate) for optimal efficacy 5.

Monitoring After Flare Resolution

• Assess disease activity every 1–3 months using validated composite scores (DAS28, SDAI, or CDAI) 5.
• The primary goal remains sustained clinical remission, with low disease activity as an acceptable alternative 5.
• Do not continue ineffective therapy beyond 3–6 months, as prolonged active disease leads to irreversible joint damage 5.

Glucocorticoid Tapering Strategy

• Taper glucocorticoids as rapidly as clinically feasible once the flare is controlled 5.
• Glucocorticoids should serve only as short-term bridging therapy while DMARDs are optimized, not for long-term maintenance 4, 7.
• In clinical trials, most patients starting initial GC bridging are able to stop GCs within 12 months (22% continued) to 24 months (10% continued) 7.
• Long-term glucocorticoid use (if unavoidable) should not exceed 0.1 mg/kg/day and only if needed to achieve symptom control while optimizing DMARDs 1.

Critical Safety Considerations

• Glucocorticoid safety risks increase with dose and duration, including osteoporotic fractures, serious infections, diabetes, and mortality 7.
• For patients with gastric ulcer history, provide mandatory high-dose proton-pump-inhibitor therapy when using glucocorticoids or NSAIDs 4.
• JAK inhibitors carry specific risks of MACEs, malignancies, and thromboembolic events that must be weighed against benefits, particularly in patients over 65 years or with cardiovascular risk factors 6.

Common Pitfalls to Avoid

• Do not treat flares with glucocorticoids alone without addressing inadequate DMARD therapy—the flare indicates your disease-modifying strategy has failed 5.
• Do not delay DMARD escalation beyond 3–6 months of inadequate response, as this wastes the critical treatment window and allows irreversible damage 5.
• Do not use hydroxychloroquine monotherapy for typical RA flares; its efficacy is limited and reserved only for very mild disease 5.
• Do not prescribe long-term glucocorticoids as maintenance therapy; they should be tapered first in any de-escalation strategy 5.